Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
Microbiology, Fujita Health University Hospital, Toyoake, Aichi, Japan.
BMJ Case Rep. 2024 Aug 3;17(8):e261578. doi: 10.1136/bcr-2024-261578.
A man in his 70s was admitted to an intensive care unit with severe COVID-19 and treated with dexamethasone and tocilizumab. After recovery from COVID-19, he developed bacteraemia and non-occlusive mesenteric ischaemia, with fatal outcome. He had been prescribed MIYAIRI 588 fine granules as probiotics for a month. The genome sequences of the isolate from the blood culture and MIYAIRI 588 fine granules were identical by single nucleotide polymorphism analysis. This is the first case of definitive probiotics-related bacteraemia after treatment of severe COVID-19.
一位 70 多岁的男性因严重 COVID-19 入住重症监护病房，接受地塞米松和托珠单抗治疗。在 COVID-19 康复后，他发生菌血症和非闭塞性肠系膜缺血，最终死亡。他曾被处方 Miyairi 588 细颗粒作为益生菌治疗一个月。通过单核苷酸多态性分析，血液培养物和 Miyairi 588 细颗粒的分离株的基因组序列完全相同。这是首例严重 COVID-19 治疗后与益生菌相关的明确菌血症病例。
